| Texto completo | |
| Autor(es): |
Baptistella, Antuani R.
;
Salles Dias, Marcos Vinicios
;
Aguiar, Jr., Samuel
;
Begnami, Maria D.
;
Martins, Vilma R.
Número total de Autores: 5
|
| Tipo de documento: | Artigo Científico |
| Fonte: | ANTI-CANCER DRUGS; v. 27, n. 8, p. 734-737, SEP 2016. |
| Citações Web of Science: | 2 |
| Resumo | |
The A33 protein, expressed in colorectal tumors, is a target for improving treatment of patients with colorectal cancer. Over the last decade, studies have tested anti-A33 antibody as a therapeutic agent for these patients. Preclinical results were promising, but clinical trials did not confirm positive results. Here, immunohistochemistry in colorectal cancer tissue showed that samples from well-differentiated tumors presented a strong A33 membrane staining, whereas poorly differentiated tumors and mucinous adenocarcinomas showed weak cytoplasmic and nuclear staining. Moderately differentiated tumors presented variable staining. We suggest that in future clinical trials, patients should be selected on the basis of membrane expression of A33. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. (AU) | |
| Processo FAPESP: | 13/04913-0 - Identificação e caracterização das vesículas extracelulares secretadas por células de câncer retal e sua relação com a resposta ao tratamento neoadjuvante |
| Beneficiário: | Antuani Rafael Baptistella |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 09/14027-2 - Mecanismos associados à função da proteína prion e seu ligante STI1/Hop: abordagens terapêuticas |
| Beneficiário: | Vilma Regina Martins |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |